Medicine composition containing sulfonylurea compounds and phenoxy acid type compounds

A technology of sulfonylureas and phenoxyaromatic acids, which is applied in the directions of drug combinations, medical preparations containing active ingredients, and pharmaceutical formulations, etc. Impair, improve patient compliance

Active Publication Date: 2010-09-01
SHENZHEN AUSA PHARM CO LTD +2
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, there are very few pharmaceutical compositions for treating hyperglycemia and hyperlipidemia simultaneously at present

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 Prevention and treatment effect of glimepiride and fenofibrate on rats with hyperglycemia and hyperlipidemia

[0029] Replication of type 2 diabetes rat model with hyperlipidemia, refer to the literature (Wang Qinmao, et al. Chinese Pharmacology Bulletin, 2002; p18(4): 456-9), 120 male Wistar rats, after 7 days of adaptive feeding 15 were left as the normal group, and the remaining rats were injected with 1% streptozotocin solution 30 mg / kg through the tail vein, and the rats with abnormal glucose tolerance (IGT) were selected after 3 weeks to feed with high-calorie feed (the formula is: cholesterol 1 %, propylthiouracil 0.2%, sodium cholate 0.3%, lard 10%, basal feed 88.5%), the normal group was given basal feed. The animals were fed individually, and the glucose tolerance test was done at 6 and 13 weeks after streptozotocin injection. Fasting blood glucose (FBG), insulin and blood lipids (triglycerides TG, total cholesterol TC) were detected at the 13th wee...

Embodiment 2

[0046] Example 2 The combined use of glimepiride and fenofibrate prevents and treats diabetes and its complications.

[0047] 323 patients with type 2 diabetes and hyperlipidemia included 166 males and 157 females, aged 41 to 65 years (55.5±4.8 years), and the course of disease was 4 to 18.8 years (7.8±3.7 years). Patients with pre-existing complications were excluded based on a thorough physical examination. Diabetic patients were randomly divided into control group and treatment group according to blood glucose and blood lipid levels. There was no significant difference between the two groups in terms of age, gender, weight, blood lipid, blood pressure, course of disease, condition, and conventional treatment drugs. The control group took 2-4 mg of glimepiride orally on the basis of conventional treatment, and the treatment group took 2-4 mg of glimepiride + 200 mg of fenofibrate on the basis of conventional treatment for more than 2 years. physical examination. The statis...

Embodiment 3

[0053] Example 3 Prevention and treatment effect of gliquidone combined with fenofibrate on rats with hyperglycemia and hyperlipidemia

[0054] The replication method of the rat model of type 2 diabetes with hyperlipidemia is the same as that in Example 1. The type 2 diabetic rats were randomly divided into model group, gliquidone group (3.0mg / kg), fenofibrate group (30mg / kg), gliquidone+ Fenofibrate group (3.0mg / kg+30mg / kg), 15 rats in each group, and a normal control group, the model group and the normal group were given equal volume of normal saline. Oral administration, once a day, for 13 weeks. Urine was collected for 24 hours, and urine MALB, α1-MG, and urine creatinine were measured according to the kit instructions. Orbital blood was collected to measure blood glucose and insulin levels, and ISI was calculated. After fasting for 12 hours, blood was collected to measure serum TC and TG, blood creatinine and blood BUN were measured, and serum creatinine clearance (Ccr)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A medical composition used for preparing the medicines for preventing and treating hyperglycemia, hyperlipemia and cerebrovascular and cardiovascular diseases caused by said hyperglycemia and / or hyperlipemia contains the glimepiride or its active metabolite or its derivative, phenyloxy acid type compounds or their active metabolits or salts or esters, and the pharmacologically acceptable carrier.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing sulfonylureas and phenoxyacids, and the use of the pharmaceutical composition in preparing medicines. belongs to the field of pharmacy. Background technique [0002] Diabetes and dyslipidemia are the main diseases that endanger human health today, and they are independent pathogenic factors of coronary heart disease. Epidemiological studies have found that most people have both hyperglycemia and hyperlipidemia. The prospective cohort study of cardiovascular disease in multiple provinces and cities in China (CMCS study) investigated the risk factors of cardiovascular disease among 28,594 natural populations aged 35 to 64 in 11 provinces and cities in 1992, and found that diabetic patients complicated with dyslipidemia The proportion of patients with diabetes (48.8%) was significantly higher than that of non-diabetic patients with abnormal blood lipids (34.0%), and 34.6% of diabetic patie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K31/17A61K31/4704A61K31/216A61K31/192A61P3/10A61P3/06
CPCY02A50/30
Inventor 陈光亮王琳琳段炎炎刘海鹏李莉胡容峰谷仿丽
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap